About CytoLogix
CytoLogix is a Healthcare company based in Cambridge (United States) founded in 1996, and was acquired by Dako in September 2002. Tissue-staining instruments for cancer diagnosis were developed. CytoLogix has raised $26 million across 3 funding rounds from investors including Boston University, National Cancer Institute and Dako. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Pan Cancer. Its competitors include GRAIL, Color and Earli; 3 of its 3 listed competitors have raised funding.
Company details
CytoLogix was founded in 1996 in Cambridge, United States, as a private company focused on laboratory instrumentation for non-routine complex stains. The Artisan instrument was developed for immunohistochemical and special stains, enabling walk-away automation primarily in cancer diagnostics. Operations centered on this product line, which was sold to DakoCytomation in September 2002. The domain cytologix.com was associated with the company.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website cytologix.com
- Acquired by Dako (Sep 2002)
- Total Equity Funding$26M (USD)
in 3 rounds
- Latest Funding Round$2.75M (USD), Debt – Conventional
Jul 2002
- InvestorsBoston University
& 7 more
- Acquired byDako
(Sep 2002)
Funding Insights of CytoLogix
CytoLogix has successfully raised a total of $26M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.75 million completed in July 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 3
- Last Round Debt – Conventional — $2.75M
- Investors Count 7
All 3 funding rounds of CytoLogix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2002 | $2.75M | Debt – Conventional | – | – | – |
| Jan 2001 | $26M | Series B | – | – | |
| Oct 2000 | Grant | – | – |
8 investors in total: 8 institutional.
Investors in CytoLogix
CytoLogix has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston University, National Cancer Institute and Dako.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US healthcare investments are managed by EGS Healthcare Capital Partners. | egshealthcare.com | Norwalk, United States | ||
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
VC firm making investment in early stage startups in the US | atvcapital.com | Menlo Park, United States | ||
Tech focused early stage VC firm investing in the US | mass-ventures.com | Boston, United States | ||
| hamquist.com | ||||
Multiple courses and degrees are offered across diversified academic streams. | 1869 | bu.edu | United States | |
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Reagents, instruments, software, and consulting for cancer diagnostics are supplied. | 1996 | dako.com | Glostrup, Denmark |
Investor details for CytoLogix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CytoLogix
4 dated milestones of CytoLogix across 6 years, from founding to its latest funding, stage changes and deals.
- Founded CytoLogix is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional, of $2.7M.
- Exit Acquired by Dako.
Competitors of CytoLogix
CytoLogix has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Color and Earli.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| earli.com | 2018 | San Francisco, United States | $40M | 38 | Early cancer detection tests are developed using synthetic biomarkers. |
Detailed competitors of CytoLogix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as CytoLogix (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CytoLogix
CytoLogix was founded in 1996 and raised its 1st funding round 4 years after it was founded.
CytoLogix is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
CytoLogix is a funded company, having raised a total of $26M across 3 funding rounds to date.
CytoLogix was founded in 1996 in Cambridge, United States, as a private company focused on laboratory instrumentation for non-routine complex stains. The Artisan instrument was developed for immunohistochemical and special stains, enabling walk-away automation primarily in cancer diagnostics. Operations centered on this product line, which was sold to DakoCytomation in September 2002. The domain cytologix.com was associated with the company.
CytoLogix has 8 investors. Key investors include Boston University, National Cancer Institute, Dako, EGS Healthcare Capital Partners, and Oxford Bioscience Partners.
Yes. CytoLogix was acquired by Dako in September 2002.